NASDAQ:ACST • CA00430K8656
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACASTI PHARMA INC (ACST).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-09-26 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-07 | Craig-Hallum | Initiate | Buy |
| 2023-02-15 | EF Hutton | Reiterate | Buy |
| 2022-12-19 | EF Hutton | Initiate | Buy |
| 2022-12-15 | HC Wainwright & Co. | Initiate | Buy |
| 2021-12-22 | Oppenheimer | Initiate | Outperform |
| 2021-12-21 | Oppenheimer | Initiate | Outperform |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 200K | -100.00% | 1.239M | 39.743M 3,107.67% | 72.783M 83.13% | 101.21M 39.06% | 118.83M 17.41% | ||||||
| EBITDA YoY % growth | -31.34M -136.17% | -22.12M 29.42% | -9.8M 55.70% | N/A -56.53% | N/A -18.19% | N/A 37.36% | -23.903M -110.48% | -26.838M -12.28% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.67M -119.35% | -24.44M 27.41% | -10.72M 56.14% | -17.238M -43.10% | -20.706M -18.97% | -16.61M 37.72% | -27.257M -139.79% | -26.423M 3.06% | -10.098M 61.78% | 8.564M 184.81% | 33.365M 289.60% | 47.922M 43.63% | |
| Operating Margin | N/A | N/A | -5,360.00% | N/A | N/A | N/A | N/A | -2,132.59% | -25.41% | 11.77% | 32.97% | 40.33% | |
| EPS YoY % growth | -9.12 7.63% | N/A -240.89% | N/A 80.95% | -0.86 85.53% | -2.69 -214.29% | -1.98 26.59% | -2.19 -11.02% | -1.78 19.11% | -0.16 90.82% | 0.61 474.72% | 1.56 155.09% | 2.15 37.91% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.64 -238.41% | -0.43 -42.68% | -0.33 -83.49% | -0.29 21.89% | -0.33 48.63% | -0.40 6.45% | -0.39 -16.67% |
| Revenue Q2Q % growth | 1.239M | ||||||
| EBITDA Q2Q % growth | -6.709M -225.70% | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.989M -237.63% | -6.193M -103.51% | -6.193M -89.79% | -5.505M -10.92% | -6.193M 11.39% | -7.569M -22.22% | -7.156M -15.56% |
All data in USD
7 analysts have analysed ACST and the average price target is 8.16 USD. This implies a price increase of 142.14% is expected in the next year compared to the current price of 3.37.
ACASTI PHARMA INC (ACST) will report earnings on 2024-11-11, before the market open.
The consensus EPS estimate for the next earnings of ACASTI PHARMA INC (ACST) is -0.64 USD and the consensus revenue estimate is 0 USD.